Growth of Targeted Therapy Requires More Nuanced Treatment Considerations in NSCLC
*November 2020* The role of targeted therapy is rapidly expanding in the treatment paradigm of patients with non–small cell lung cancer (NSCLC), said D. Ross Camidge, MD, PhD, who added that among multiple therapeutic options for common aberrations, such as ALK, ROS1, BRAF, and MET, treatment selection should be based on more than…
laurabbook@gmail.comJanuary 6, 2021










